Ipsen news from FierceBiotech
NewsTercica shares skyrocket following takeover bid
Moving fast, investors swiftly bid up the value of Tercica's stock yesterday afternoon after hearing that France's Ipsen would pay $9 a share to acquire all the stock in the company it didn't already Read more...
Ipsen inks a string of deals in expansion effort
France's Ipsen is buying out Tercica in a $404 million deal, one of three new pacts designed to Read more...
Ipsen clears FDA hurdle, gains $25M for Reloxin BLA
France's Ipsen gained $25 million from Medicis Pharmaceutical on the news that the FDA has accepted the BLA filing for Reloxin, a next-gen competitor to Allergan's Botox. And analysts say the therapy Read more...
ALSO NOTED: Ipsen files new BLA;Amgen selects Vectibix test; and much more...
> Ipsen says it has submitted a new BLA for Reloxin, addressing concerns raised by the FDA when the agency declined to file its BLA in January. Read more...
Medicis shares sink as FDA rejects BLA
Medicis Pharmaceutical earned an "incomplete" grade on its latest BLA. The FDA has refused to accept the application for Reloxin--botulinum toxin type A--for a variety of shortfalls, including a gap Read more...
Pfizer inks $25M research deal
Continuing the hot trend of biopharma companies partnering with research institutions, Pfizer has Read more...
Ipsen, Salk Institute ink research pact
Paris-based Ipsen and the nonprofit Salk Institute have teamed up to create the Ipsen Life Sciences Program at The Salk Institute. Over the next three to five years, Ipsen will pay Salk $10 million Read more...
FDA approves Tercica's growth disorder drug
The FDA has approved Tercica's Somatuline Autogel, an injectable treatment for adult patients with acromegaly. Acromegaly is a rare disorder caused by too much growth hormone, resulting in enlarged Read more...
| Press ReleasesPRESS RELEASE: Ipsen: Somatuline Depot Receives Marketing Approval in the United States for the Treatment of Acromegaly Ipsen: Somatuline Depot Receives Marketing Approval in the United States for the Treatment of Acromegaly PARIS -- Aug 31, 2007 - Regulatory News: Ipsen today announced that the U.S. Food and Drug Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets